HPTN 083

A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Study Summary
Study Documents - Study Details* - Key Study Personnel* - Study SitesPublications
*Authenticated users only (create your account here)

>> Visit the Study Website <<



What is HPTN 083?

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW).

Men of 083Who is participating in the study?

HPTN 083 will enroll approximately 5,000 HIV-uninfected MSM and TGW at risk for acquiring HIV infection, ages 18 or older at sites in the Americas, Asia and South Africa.

Why is HPTN 083 important?

PrEP agents are needed that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.

What will happen during the study?

Once randomized to one of two arms, participants will move through the steps below and followed for approximately 4 years (active drugs are shown in bold text) as follows:

Step 1:

Arm A – Daily oral CAB (30 mg tablets) and oral TDF/FTC placebo for five weeks

Arm B – Daily oral TDF/FTC (300 mg/200 mg fixed-dose combination tablets) and oral CAB placebo for five weeks


Step 2:

Arm A – CAB LA (600 mg as a single intramuscular [IM] injection at two time points 4 weeks apart and every 8 weeks thereafter) and daily oral TDF/FTC placebo.

Arm B – Daily oral TDF/FTC (300/200 mg fixed-dose combination tablets) and IM placebo at two time points 4 weeks apart and every 8 weeks thereafter (matching vehicle, identical volume as active injectable product in Arm A).

Participants in both arms of Step 2 will be followed for approximately three years. 


Step 3:

Both arms: Open-label daily oral TDF/FTC no later than 8 weeks after the last injection (in order to cover the pharmacokinetic (PK) tail for Arm A participants), for approximately one year.


HPTN 083 schema